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Abstract
Background: HIV-associated cognitive impairment has declined since the introduction of combination antiretroviral
treatment (cART). However, milder forms of cognitive impairment persist. Inflammation in the cerebrospinal fluid
(CSF) has been associated with cognitive impairment, and CSF neurofilament light chain protein (NFL) and CSF
neopterin concentrations are increased in those patients. Microbial translocation in HIV infection has been
suggested to contribute to chronic inflammation, and lipopolysaccharide (LPS) and soluble CD14 (sCD14) are
markers of microbial translocation and the resulting monocyte activation, respectively. We hypothesised that
microbial translocation contributes to inflammation and axonal damage in the central nervous system (CNS) in
untreated HIV infection.
Methods: We analyzed paired samples of plasma and CSF from 62 HIV-infected, untreated patients without
cognitive symptoms from Sahlgrenska University Hospital, Gothenburg, Sweden. Measurements of neopterin and
NFL in CSF were available from previous studies. Plasma and CSF sCD14 was measured using ELISA (R&D,
Minneapolis, MN), and plasma and CSF LPS was measured using LAL colorimetric assay (Lonza, Walkersville, MD,
USA). Univariate and multivariate regression analyses were performed.
Results: LPS in plasma was associated with plasma sCD14 (r = 0.31, P = 0.015), and plasma sCD14 was associated
with CSF sCD14 (r = 0.32, P = 0.012). Furthermore, CSF sCD14 was associated with NFL (r = 0.32, P = 0.031) and
neopterin (r = 0.32, P = 0.012) in CSF. LPS was not detectable in CSF. In a multivariate regression model CSF sCD14
remained associated with NFL and neopterin after adjusting for age, CD4+ cell count, and HIV RNA in CSF.
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Conclusions: In a group of untreated, HIV-infected patients LPS was associated with sCD14 in plasma, and plasma
sCD14 was associated CSF sCD14. CSF sCD14 were associated with markers of CNS inflammation and axonal
damage. This suggest that microbial translocation might be a driver of systemic and CNS inflammation. However,
LPS was not detectable in the CSF, and since sCD14 is a marker of monocyte activation sCD14 may be increased
due to other causes than microbial translocation. Further studies regarding cognitive impairment and biomarkers
are warranted to fully understand causality.
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Background
Prior to introduction of combination antiretroviral treat-
ment (cART) a large proportion of HIV-infected patients
developed severe neurocognitive disorders [1, 2]. With
the introduction of cART, the incidence of severe HIV-
associated neurocognitive disorders decreased, while
milder types persists [3, 4].
A number of studies suggest that cognitive impairment
may be caused by inflammation in the central nervous
system (CNS) [5–8]. Thus, biomarkers of inflammation in
the cerebrospinal fluid (CSF) have been associated with
cognitive impairment. One such biomarker is neopterin, a
marker of monocyte activation which has been found to
be elevated in the CSF of HIV-infected patients. The con-
centration of neopterin decreases after initiation of cART,
although it does not reach the concentrations observed in
HIV-uninfected persons [9, 10], hence indicating persist-
ent CNS inflammation [11]. Neurofilament light chain
protein (NFL) is a marker of CNS axonal damage that has
been associated with CNS inflammation. NFL is increased
in HIV-infected patients with cognitive impairment or op-
portunistic CNS infections [12–17].
Systemic inflammation in HIV-infected patients has
been reported repeatedly [18–20] and is believed to be
partly caused by microbial translocation. Microbial
translocation and immune activation are predictors of
disease progression and non-AIDS-related morbidity in
HIV infection [21–23]. During acute HIV infection, the
gastrointestinal mucosa is depleted of T cells leading to
translocation of microbial products such as lipopolysac-
charide (LPS) into the systemic circulation [24–28]. LPS
activates cells of the innate immune system by binding
to Toll-like receptor-4 (TLR-4). CD14 needs to be
present in order for LPS to activate the receptor. CD14
is expressed on monocytes, macrophages, and neutro-
phils, and upon stimulation by LPS, as well as other mi-
crobial products, CD14 is secreted and cleaved from the
cells as soluble CD14 (sCD14) [29].
We hypothesised that microbial translocation contrib-
utes to inflammation in the CNS of HIV-infected patients.
We therefore aimed to investigate if markers of microbial
translocation (LPS) and monocyte activation (sCD14)
were detectable in CSF and to determine possible
associations between these markers and markers of
inflammation and axonal damage in the CNS (NFL, neop-
terin) in untreated HIV-infected patients.
Methods
Participants
Since 1985, HIV-infected patients in Gothenburg,
Sweden have been included in a longitudinal study that
includes serial sampling of CSF, plasma, and serum. This
cohort has previously been described in detail [14].
Lumbar punctures are performed in a standardized man-
ner at least annually and more frequently in connection
with antiretroviral treatment initiation or change in
treatment. CSF and blood samples are stored at −80 °C
in batches. Both asymptomatic and symptomatic pa-
tients are included, and as of December 2014 the cohort
included 494 patients who had undergone 1805 lumbar
punctures. Patients were clinical assessed for neurocog-
nitive function (reporting no challenges in regard to
daily living or work).
From this cohort 20 untreated HIV-infected patients
without CNS opportunistic infection but with pleocyto-
sis the CSF (>5 cells/μL) indicating HIV-induced inflam-
mation was included in a pilot study in order to
determine if it was possible to detect sCD14 and LPS in
CSF during HIV infection. The 20 participants from the
pilot study did not participate in the following analyses.
Afterwards, 62 untreated, HIV-infected patients with-
out cognitive symptoms or CNS opportunistic infections
with samples collected between 2004 and 2014 were se-
lected for further analyses. Untreated patients were se-
lected to avoid confounding effects of cART on
microbial translocation and inflammation. 30 patients
had pleocytosis.
In order to determine if CD4+ cell count affected either
microbial translocation or monocyte activation, patients
were selected to have either CD4+ cell count >350 cells/
μL (n = 31, CD4+ cell count range 380–1400, median 530
cells/μL) or CD4+ cell count <200 cells/μL (n = 31, CD4+
cell count range 0–190, median 100 cells/μL). Groups
were matched on gender, age, and CSF leucocyte count.
The selection was done randomly from the list of patients
fulfilling the inclusion criteria (Table 1). Five patients with
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low CD4+ cell count were treated with trimetoprim/sulfa-
metoxazole including four as prophylaxis against Pneumo-
cystis jirovecii, and one patient was treated for Pneumocystis
pneumonia. Furthermore, one patient was treated for
tuberculosis.
The study was approved by the Regional Ethical Re-
view Board in Gothenburg (Ö 588–01) and was per-
formed in accordance with the Helsinki Declaration. All
blood and CSF samples were obtained after informed
consent of subjects under the IRB-approved protocol.
Markers of axonal damage, inflammation, and HIV-related
factors
CSF NFL was measured using a sensitive sandwich
enzyme-linked immunosorbent assay (ELISA) (NF-light®
ELISA kit, UmanDiagnostics AB, Umeå, Sweden) as pre-
viously described [12, 30]. CSF neopterin was measured
using a commercially available radioimmunoassay (Hen-
ningtest Neopterin, BRAHMS, Berlin, Germany) [15].
HIV-1 RNA in CSF and plasma were quantified with
Roche Amplicor Monitor assay version 1.5 (Hoffman
La-Roche, Basel, Switzerland) with a detection limit of
20 copies/mL. Furthermore, routine assessments in-
cluded CSF white blood cell count and peripheral blood
CD4+ cell count as previous described [31].
Valid measurement of neopterin in plasma and CSF,
NFL and leucocyte count in CSF were available in 60,
61, 46, and 60 patients, respectively.
Markers of microbial translocation and monocyte
activation
LPS in plasma and CSF was analysed by the Limulus ame-
bocyte lysate colorimetric assay (Lonza, Walkersville, MD)
according to the manufacturer’s instructions and with the
following modifications: Samples were diluted 10-fold to
avoid interference with background colour, and preheated
to 68 °C for 12 min prior to analysis to dissolve immune
complexes, as previously described [32, 33].
Soluble CD14 in plasma and CSF was analysed using
ELISA according to the manufacturer’s instructions
(R&D, Minneapolis, MN).
Statistics
Data are given as median (interquartile range (IQR)). A P
value ≤0.05 was considered significant. When comparing
groups, the Student T-test and Mann Whitney U-test was
used as appropriate. Uni- and multivariate linear regres-
sion models were used to assess associations and adjusted
for possible confounders. When appropriate data were
log-transformed (ln). In order to investigate possible asso-
ciations between microbial translocation and inflamma-
tion in the CSF, multivariate linear regression models were
performed with NFL and neopterin as the dependent vari-
ables, and sCD14 in the CSF was added as an independent
variable. The model was adjusted for age, HIV RNA in the
CSF, and CD4+ cell count. Since patients were included in
two CD4+ cell count groups, CD4+ cell count was added
to the model as both a continuous variable and as a nom-
inal variable. Only the continuous variable was significant
and therefore used in the final model. The analyses were
performed using IBM SPSS 22.0 (Statistics for Windows,
IBM Corp., Armonk, NY).
Results
Characteristics of the study population
The pilot study included 20 untreated, asymptomatic,
HIV-infected patients with CSF pleocytosis as a sign of
HIV-induced inflammation. Both LPS and sCD14 was
detectable in all plasma samples. However, LPS was not
detectable in any CSF samples whereas CSF-sCD14 was
detectable in all CSF samples (data not shown). Hence,
only sCD14 was measured in CSF in the subsequent
analyses.
Table 1 Characteristics of the study population
Untreated HIV-infected patients
Characteristics Total sample (n = 62)
Age (years, range) 39 (24–68)
Gender (male, n(%)) 32 (52)
CD4+ cell count (cells/μL) 190 (98–530)
HIV RNA blood (copies/mL) 39587 (8799–172541)
HIV RNA CSF (copies/mL) 4690 (749–28150)
Leucocytes CSF (cells/μL) 5 (1–9)
Serum albumin (g/L) 39 (36–42)
CSF albumin (mg/L) 165 (136–243)
Albumin ratio 3.5 (4.1–5.9)
Mode of transmission (n (%)):
Heterosexual 49 (79)
MSM 11 (18)
IV drug users 2 (3)
AIDS defining diseases (n (%)):
Pneumocystis jirovecii pneumonia 1 (2)
Wasting syndrome 2 (3)
Tuberculosis 1 (2)
Biomarkers
LPS plasma (pg/mL) 102 (78–121)
sCD14 plasma (ng/mL) 2382 (1941–3111)
sCD14 CSF (ng/mL) 222 (161–373)
Neopterin plasma (nmol/L) 12 (9–23)
Neopterin CSF (nmol/L) 15 (8–22)
NFL CSF (ng/L) 410 (250–635)
Data is given as median (IQR), unless otherwise stated
LPS lipopolysaccharide, NFL neurofilament light, CSF cerebrospinal fluid, MSM
men who have sex with men, IV intravenous
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Samples from 62 untreated, HIV-infected patients
without clinical evidence of impaired cognitive function
and with CD4+ cell count either above 350 or below 200
cells/μL were selected for further analysis. Characteris-
tics of the study population are shown in Table 1.
Detection of LPS in plasma and sCD14 in plasma and CSF
Valid measurement of LPS in plasma and sCD14 in
plasma was obtained in all 62 participants whereas
sCD14 in CSF was obtained in 61 participants.
Patients with plasma sCD14 above median had higher
plasma LPS compared to patients with sCD14 below me-
dian (91 pg/mL vs. 117 pg/mL, P = 0.042), whereas there
were no differences in age, gender, CD4+ cell count, or
plasma HIV RNA between these two groups. However,
when dividing the patients into two groups with sCD14 in
CSF above or below median, no differences were found in
regard to age, gender, CD4+ cell count, plasma HIV RNA,
plasma LPS, or CFS HIV RNA (all P values >0.05).
Soluble CD14 and immune deficiency
Increased concentrations of sCD14 in plasma was found in
patients with CD4+ cell count <200 compared to patients
with CD4+ cell count >350 (median of 2579 ng/mL (IQR
2061–3641) vs. 2357 ng/mL (IQR 1174–2959) (P = 0.031)).
Furthermore, concentration of sCD14 in CSF was 308
(IQR 196–385) in the group with CD4+ cell count <200
vs. 201 (IQR 90–317) in the group with CD4+ cell count
>350 (P = 0.015). Leucocyte cell counts in CSF were me-
dian 3 cells/μL (IQR 1–11) and 5 cells/μL (IQR 4–9) (P =
0.406) in the group with CD4+ cell count <200 vs. the
group with CD4+ cell count >350. Concentrations of CSF
sCD14 was associated with CSF leucocyte cell count in a
univariate analysis (r = 0.73, P = 0.049).
Markers of microbial translocation associated with
inflammation in the CNS
Univariate analyses demonstrated associations between
plasma LPS and plasma sCD14 (r = 0.31, P = 0.015), as
well as borderline significant association with CSF
sCD14 (r = 0.24, P = 0.059). Furthermore, plasma
sCD14 was associated with CSF sCD14 (r = 0.32, P =
0.012, Fig. 1) and tended to correlate with plasma
neopterin (r = 0.24, P = 0.060). Importantly, CSF sCD14
was associated with a higher concentration of both
NFL (r = 0.32, P = 0.031) and neopterin in the CSF (r =
0.32, P = 0.012, Fig. 1).
Fig. 1 Univariate analyses. Markers of microbial translocation (LPS), monocyte activation (sCD14), axonal damage (NFL), and CNS inflammation
(neopterin) were measured in paired samples of cerebrospinal fluid (CSF) and plasma from 62 untreated HIV-infected patients. Univariate analysis
were performed after Log(ln) transformation due to skewed data. (a) plasma LPS and plasma sCD14, (b) plasma sCD14 and CSF sCD14, (c) CSF
sCD14 and CSF NFL, (d) CSF sCD14 and CSF neopterin. CSF = cerebrospinal fluid, LPS = lipopolysaccharide, NFL = neurofilament light chain,
sCD14 = soluble CD14
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In a multivariate linear regression model, CSF sCD14
remained associated with NFL (P = 0.039) and neopterin
(P = 0.002) when adjusted for age, CD4+ cell count, and
HIV RNA in CSF. In line with previous studies, higher
age (P = 0.001) and lower CD4+ cell count (P = 0.001)
were associated with higher NFL in multivariable ana-
lysis [12]. Higher HIV RNA in CSF (P < 0.001) and lower
CD4+ cell count (P < 0.001) were associated with higher
neopterin. When LPS was added to the model, no asso-
ciation was found with NFL or neopterin.
Discussion
In this study of untreated, HIV-infected patients, sCD14,
a marker of microbial translocation and monocyte acti-
vation was detectable in both plasma and CSF. High
CSF and plasma sCD14 was not explained by higher
HIV RNA or lower CD4+ cell counts, while a significant
association between plasma sCD14 and LPS was found.
Furthermore, significant associations between CSF
sCD14 and markers of inflammation and axonal damage
in the CSF were found, independent of age, HIV RNA,
and CD4+ cell count. Hence, it is possible that elevated
monocyte activation, partly driven by microbial trans-
location, may contribute to the pathogenesis in CNS by
promoting inflammation.
Infection of the CNS occurs early during HIV infec-
tion [34, 35]. HIV enters the CNS unassisted or in in-
fected monocytes that cross the blood–brain barrier
(BBB) [36–38]. In the CNS, HIV and migrated immune
cells lead to the production of pro-inflammatory cyto-
kines and further immune activation. Inflammation in
the CNS creates a neurotoxic environment resulting in
damage of the neurons [39]. Increased NFL reflects
axonal damage [40], and neopterin is a marker of acti-
vated monocytes that is used to assess inflammation in
the CNS in HIV-infected patients. In pre-cART studies
high concentration of HIV RNA in the CSF was associ-
ated with severity of cognitive impairment [37, 38].
However, the association between HIV RNA and cogni-
tive impairment in the cART era has not been as strong
or consistent, indicating that other factors may also play
a role in the development of HIV-associated cognitive
impairment [38, 41–43].
Immune activation and inflammation is a hallmark of
HIV infection and is caused by several factors including
HIV replication, ART toxicity, co-infections, loss of
regulatory cells, and microbial translocation [44]. Deple-
tion of immune cells around the gastrointestinal tract
leads to increased permeability for microbial products
like LPS [45]. LPS is a part of the Gram negative bacter-
ial wall and is frequently used in studies as a marker of
microbial translocation. LPS cannot penetrate a normal
functioning BBB, however, inflammation caused by LPS
may make the BBB more permeable for HIV and
activated monocytes [46, 47]. To our knowledge LPS
measurements in the CSF have not previously been
reported.
The binding of LPS to TLR-4 results in secretion of
pro-inflammatory cytokines and sCD14 from activated
monocytes. We found significant associations between
plasma LPS and plasma sCD14 as well as borderline sig-
nificant association with CSF sCD14. Activated mono-
cytes that have migrated to the CNS is the most likely
source of sCD14 in the CSF, as sCD14 has not been re-
ported to be produced from residing monocytes (micro-
glia and astrocytes) [48]. Neopterin, which also is a
marker of monocyte activation, is on the other hand
produced by residing monocytes in the CSF [49]. This
makes sCD14 an interesting biomarker in the CSF, as it
potentially reflects the level of monocyte migration into
the CNS supported by a positive correlation between
CSF cell count and CSF sCD14. However, CD14 has
been shown to possess several other functions besides
binding LPS. CD14 also acts as a co-receptor for several
other TLRs and microbial products which may explain
the lack of consistency in studies investigating LPS in as-
sociation with CD14 [50, 51].
Several studies have shown that markers of microbial
translocation are associated with cognitive impairment in
HIV-infected patients [7, 8, 52–54]. Thus, CNS HIV Anti-
Retroviral Therapy Effects Research (CHARTER) and The
National NeuroAIDS Tissue Consortium (NNTC) groups
have shown that LPS and sCD14 in plasma and in the
CSF were increased in patients with impaired cognitive
function [7, 8, 53]. Furthermore, increased sCD14 persists
even after effective cART [55]. We found strong associa-
tions between CSF sCD14 and NFL, even after adjustment
for age, HIV RNA, and CD4+ cell count, indicating that
activated monocytes may contribute to axonal damage in
the CNS, albeit this cross sectional study does not allow
us to determine causality. Furthermore, our findings are
supported by a recent study of CSF sCD14 and NFL in
untreated HIV-infected patients [17].
Guidelines to assess cognitive function are based on
the use of neuropsychological test [56]. Studies have
shown that even in well treated HIV-infected individuals
on cART, as many as 50 % have been reported to have
neurocognitive disorders [57–59]. However, neuro-
psychological tests are time consuming, require specia-
lised staff, and are not available in all clinical settings.
Furthermore, neuropsychological tests are not able to
differentiate between active or residual cognitive impair-
ment [60]. It has been suggested that a combination of
biomarkers could be used to assess CNS inflammation
and guide in diagnosing HIV-associated CNS damage
[61]. sCD14 could be a potential candidate as it has been
established that activated monocytes play an important
role in the pathogenesis of cognitive impairment in HIV
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infection [7, 8, 52–54], however in the present study
markers of CNS inflammation and axonal damage was
associated with CSF sCD14, but not with plasma sCD14.
The present study did not include neurocognitive testing
and only included naïve HIV-infected individuals. Data
on neurocognitive performance as well as individuals on
cART could add valuable information in future studies.
This study was limited by limited sample size and the
cross-sectional design. Furthermore, measuring micro-
bial translocation using LPS is challenging since the
method is sensitive to both time and contamination [62].
However, this method is well established in our labora-
tory with an inter assay coefficient of variation < 10 %.
Also, other microbial products besides LPS, including
peptidoglycan, Pam3CSK4, polyI:C, and CpG DNA, cross
the gastrointestinal mucosa and may activate the im-
mune system and drive inflammation [50, 51]. Recently
it was found that two types of sCD14 exits [63]. A differ-
ential measurement of these may have provided add-
itional information. Furthermore, neuropsychological
evaluation would have supplied valuable information.
Conclusion
Significant associations between sCD14 in CSF and markers
of CNS inflammation and axonal damage were found sug-
gesting that monocyte activation, possibly driven by micro-
bial translocation, may contribute to CNS inflammation.
Further investigations into the pathogenesis of cognitive
impairment in HIV infection, as well as potential bio-
markers are needed, in order to increase the understanding
and supply reliable methods of diagnosing these conditions.
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